Skip to main content
. Author manuscript; available in PMC: 2017 Jan 3.
Published in final edited form as: Liver Transpl. 2016 Jan;22(1):24–33. doi: 10.1002/lt.24366

Table 3.

Crude SVR12 among patients treated with SOF+SMV or SOF+SMV+RBV.

Population SOF+SMV SOF+SMV+RBV ALL
n/N SVR12 95% CI n/N SVR12 95% CI n/N SVR12 95% CI
Overall 105/119 88% (81, 93) 28/32 88% (71, 96) 133/151 88% (82, 93)

Tx Experience Naïve 51/57 89% (78, 96) 9/9 100% (66, 100) 60/66 91% (81, 97)
Experienced 54/62 87% (76, 94) 19/23 83% (61, 95) 73/85 86% (77, 92)

Prior PI Failure 4/8 50% (16, 84) 3/3 100% (29, 100) 7/11 64% (31, 89)

Genotype 1a 57/67 85% (74, 93) 17/20 85% (62, 97) 74/87 85% (76, 92)
1b 30/32 94% (79, 99) 9/10 90% (55, 100) 39/42 93% (81, 99)

Cirrhotic Yes 63/74 85% (75, 92) 20/23 87% (66, 97) 83/97 86% (77, 92)
No 42/45 93% (82, 99) 8/9 89% (52, 100) 50/54 93% (82, 98)

MELD < 10 19/20 95% (75, 100) 2/3 67% (9, 99) 21/23 91% (72, 99)
≥ 10 6/10 60% (26, 88) 4/5 80% (28, 99) 10/15 67% (38, 88)

Genotype: ALL Cirrhotic Experienced 33/38 87% (72, 96) 15/18 83% (59, 96) 48/56 86% (74, 94)
Non-cirrhotic Experienced 21/24 88% (68, 97) 4/5 80% (28, 99) 25/29 86% (68, 96)
Cirrhotic Naive 30/36 83% (67, 94) 5/5 100% (48, 100) 35/41 85% (71, 94)
Non-cirrhotic Naive 21/21 100% (84, 100) 4/4 100% (40, 100) 25/25 100% (86, 100)

Genotype: 1a Cirrhotic Experienced 18/22 82% (60, 95) 9/11 82% (48, 98) 27/33 82% (65, 93)
Non-cirrhotic Experienced 9/11 82% (48, 98) 2/3 67% (9, 99) 11/14 79% (49, 95)
Cirrhotic Naive 16/20 80% (56, 94) 4/4 100% (40, 100) 20/24 83% (63, 95)
Non-cirrhotic Naive 14/14 100% (77, 100) 2/2 100% (16, 100) 16/16 100% (79, 100)

Genotype: 1b Cirrhotic Experienced 10/10 100% (69, 100) 5/6 83% (36, 100) 15/16 94% (70, 100)
Non-cirrhotic Experienced 8/8 100% (63, 100) 1/1 100% (3, 100) 9/9 100% (66, 100)
Cirrhotic Naive 7/9 78% (40, 97) 1/1 100% (3, 100) 8/10 80% (44, 97)
Non-cirrhotic Naive 5/5 100% (48, 100) 2/2 100% (16, 100) 7/7 100% (59, 100)